Treatment of murine invasive candidiasis with amphotericin B and cilofungin: evidence for enhanced activity with combination therapy.
The in vivo interactions of cilofungin, an echinocandin antifungal agent, and amphotericin B, a polyene derivative, in a murine model of disseminated candidiasis have been investigated. While single therapy with either drug alone prolonged survival of infected mice, kidney colony counts were not appreciably reduced. In contrast, combination therapy, especially at higher doses of both drugs, resulted in significant prolongation of survival and suppression of growth of yeast cells in the kidneys. Combination therapy of experimental candidiasis with cilofungin and amphotericin B did not result in antagonism; rather, additive or synergistic effects were seen. Future preclinical work with other echinocandin and polyene derivatives should include studies evaluating the in vivo interactions of both classes of compounds.
Sugar
A M
AM
Evans Memorial Department of Clinical Research, Boston University Medical Center, Massachusetts.
Goldani
L Z
LZ
Picard
M
M
D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D054714:Echinocandins; D007668:Kidney / Q000382:microbiology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010455:Peptides / Q000627:therapeutic use; D010456:Peptides, Cyclic
D000935:Antifungal Agents; D054714:Echinocandins; D010455:Peptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; C042101:cilofungin